Lectrona logo Boehringer Ingelheim
Funding Opportunities for
Independent Medical
Education (IME) Grants

Independent Medical Education
(IME) Grants

Boehringer Ingelheim is proud to provide Independent Medical Education Grant support for specific independent educational activities for healthcare providers that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats.

Boehringer Ingelheim considers funding of activities both independently and through its alliance with Lilly USA, LLC in a variety of areas.

Biosimilars/CNS/Immunology

Immunology-Dermatology

1. Improve HCP knowledge of identifying best practices for assessing disease severity and diagnosis of pustular psoriasis in adult patients.

2. Enhance HCP understanding of recent pathophysiological findings in pustular psoriasis, GPP, and PPP that have informed the selection of new therapeutic targets.

3. Educate HCPs on the clinical profiles and mechanisms of action of new and emerging agents for the treatment of adults with GPP and PPP.

Cardiometabolism

To view Educational Objectives and begin the process of applying for a Medical Education grant supported by the Boehringer Ingelheim Pharmaceutical Inc and Eli Lilly and Company global Alliance agreement, click here.

Oncology

Non-Small Cell Lung Cancer

1. Increase clinicians’ understanding of the heterogeneity of disease among patients with NSCLC and the clinical impact of distinguishing between subpopulations (e.g. different histologies, different sub-types) to optimize therapeutic strategies.

2. Increase clinicians’ understanding of treating patients with EGFR positive NSCLC in the light of resistance mechanism after 1st line treatment with anti-EGFR agents.

3. Review the management of adverse events associated with the use of oral anti-EGFR agents.

4. Increase clinicians’ understanding of biology, incidence and treatment options for patients with NSCLC and uncommon EGFR mutations.

5. Increase clinicians’ awareness of Real World Data in patients with EGFR+ advanced NSCLC and its implications on patient management decisions.

6. Increase clinicians’ understanding of appropriate testing for advanced disease, emerging data on relevant genomic biomarkers and the changing treatment landscape in patients with metastatic squamous NSCLC.

Respiratory

Chronic Obstructive Pulmonary Disease (COPD)

1. Expand clinicians’ awareness of different inhaler device types and to provide practical considerations for patient prescribing.

2. Expand clinicians’ knowledge of the role of Peak Inspiratory Flow Rate.

3. Expand clinicians’ awareness to identify the role of different drug classes in COPD management as it pertains to safety and efficacy.

  a. Identify the role of dual bronchodilation for the management of COPD as it relates to the 2020 GOLD recommendation.

4. Expand clinicians’ awareness and knowledge of the GOLD/ATS/ERS guidelines for a more individualized management of COPD.

Cardiovascular

(Currently, proposals are not being accepted in this area at this time)

Back to Medical Education Grant Overview